Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Daniel Geynisman

Email
Center AffiliationsCancer Prevention and Control

Publications (58) (print view)

no pagination
Correa AF, Handorf E, Joshi SS, Geynisman DM, Kutikov A, Chen DY, Uzzo RG, Viterbo R, Greenberg RE, Smaldone MC. Differences in Survival Associated with Performance of Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. J Urol. 2018 May;199(5):1238-44.
Geynisman DM, Abbosh PH, Plimack ER, Zibelman M. Chemoimmunotherapy in Metastatic Urothelial Carcinoma. Eur Urol. 2018 May;73(5):760-2.
Geynisman DM, Meeker CR, Doyle JL, Handorf EA, Bilusic M, Plimack ER, Wong YN. Provider and patient burdens of obtaining oral anticancer medications. The American journal of managed care. 2018 Apr;24(4):e128-e133.
Ghatalia P, Zibelman M, Geynisman DM, Plimack E. Approved checkpoint inhibitors in bladder cancer: which drug should be used when?. Therapeutic advances in medical oncology. 2018 Jan;10:1758835918788310.   PMCID: PMC6066800
Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Rathmell WK, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI. Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2018 Jun;36(16):1588-93.
Joshi SS, Handorf EA, Zibelman M, Plimack ER, Uzzo RG, Kutikov A, Smaldone MC, Geynisman DM. Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis. Eur Urol. 2018 Sep;74(3):387-93.
Joshi SS, Handorf ER, Smaldone MC, Geynisman DM. What can the National Cancer Database tell us about disparities in advanced bladder cancer outcomes?. Translational Andrology and Urology. 2018 Aug;7(4):732-5.   PMCID: PMC6127539
Joshi SS, Handorf E, Strauss D, Correa AF, Kutikov A, Chen DY, Viterbo R, Greenberg RE, Uzzo RG, Smaldone MC, Geynisman DM. Treatment Trends and Outcomes for Patients With Lymph Node-Positive Cancer of the Penis. JAMA Oncol. 2018 Mar;4(5):643-9.   PMCID: PMC5885184
Pal SK, Ali SM, Yakirevich E, Geynisman DM, Karam JA, Elvin JA, Frampton GM, Huang X, Lin DI, Rosenzweig M, Lipson D, Stephens PJ, Ross JS, Miller VA, Agarwal N, Shuch B, Choueiri TK, Chung JH. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. Eur Urol. 2018 Jan;73(1):71-8.
Abbosh P, Sundararajan S, Millis SZ, Hauben A, Reddy S, Geynisman DM, Uzzo R. Molecular and Genomic Profiling to Identify Actionable Targets in Chromophobe Renal Cell Cancer. European urology focus. 2017 Jan 23;.
Ali N, Kutikov A, Geynisman DM. Resolution of a Debilitating Paraneoplastic Parkinson-like Neurological Syndrome Following Tyrosine Inhibitor Therapy and Consolidative Nephrectomy in a Patient with Advanced Clear Cell Renal Cell Carcinoma. Urol Case Rep. 2017 Sep;14:18-20.   PMCID: PMC5479944
Cahn DB, Handorf EA, Ghiraldi EM, Ristau BT, Geynisman DM, Churilla TM, Horwitz EM, Sobczak ML, Chen DY, Viterbo R, Greenberg RE, Kutikov A, Uzzo RG, Smaldone MC. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer. Cancer. 2017 Jul 25;123(22):4337-45.
Cahn DB, Handorf E, Ristau BT, Geynisman DM, Simhan J, Kutikov A, Greenberg RE, Viterbo R, Chen DY, Uzzo RG, Smaldone MC. Contemporary practice patterns and survival outcomes for locally advanced urethral malignancies: A National Cancer Database Analysis. Urol Oncol. 2017 Aug 10;35(12):670 e15-670 e21.
Correa AF, Handorf E, Joshi SS, Geynisman DM, Kutikov A, Chen DY, Uzzo RG, Viterbo R, Greenberg RE, Smaldone MC. Differences in Survival by Receipt of Lymph Node Dissection in Patients with Invasive Penile cancer: Results from the National Cancer Database. J Urol. 2017 Dec 14;.
Geynisman DM. Hope and Uncertainty in the Age of Miracles. J Palliat Med. 2017 Oct;20(10):1166-9.
Geynisman DM, de Velasco G, Sewell KL, Jacobs I. Biosimilar biologic drugs: a new frontier in medical care. Postgraduate medicine. 2017 May;129(4):460-70.
Geynisman DM, Plimack ER. Bending the Curve of Advanced Urothelial Carcinoma. J Oncol Pract. 2017 May;13(5):319-20.
Ghatalia P, Nagarathinam R, Cooper H, Geynisman DM, El-Deiry WS. Mismatch repair deficient metastatic colon cancer and urothelial cancer: a case report of sequential immune checkpoint therapy. Cancer Biol Ther. 2017 Sep 02;18(9):651-4.   PMCID: PMC5663404
Ghatalia P, Zibelman M, Geynisman DM, Plimack ER. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma. Current treatment options in oncology. 2017 Jan;18(1):7.
Hahn NM, Bivalacqua TJ, Ross AE, Netto GJ, Baras A, Park JC, Chapman C, Masterson TA, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Jones DR, McElyea K, Sandusky GE, Breen T, Liu Z, Albany C, Moore ML, Loman RA, Reed A, Turner SA, de Abreu FB, Gallagher TL, Tsongalis GJ, Plimack ER, Greenberg RE, Geynisman DM. A Phase Ii Trial of Dovitinib in Bcg-Unresponsive Urothelial Carcinoma with Fgfr3 Mutations or over-Expression: Hoosier Cancer Research Network Trial Hcrn 12-157. Clin Cancer Res. 2017 Jun 15;23(12):3003-11.   PMCID: PMC5462889
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

Daniel Geynisman Sparkline Graph

Graph Interactions

Co-Authors:

Similar Investigators:


Keywords (MeSH):


Last updated on Thursday, October 04, 2018